Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
King, A
Exogenous pulmonary surfactant: a review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker
After 39.2 months of follow-up, quizartinib more than doubled the overall survival advantage, the company stated in a press release
Step 2: Increase precursors
US$ 24.72
US$ 27.53
US$ 21.42
US$ 24.01
US$ 27.66
US$ 29.62
US$ 27.69
